Test Code 1126
Test Details
Total Testosterone
Total testosterone is a measurement of free and protein-bound testosterone and is the most potent naturally occurring androgen. It is produced by interstitial cells in the testes in response to stimulation by luteinizing hormone (LH). Testosterone is also produced by the ovary and adrenal cortex in small amounts and is responsible for the regulation of gonadotropic secretion and spermatogenesis, as well as the development of male secondary sex characteristics.
Methodology
Immunoassay – Competitive principle
Patient Preparation
None
Preferred Specimen
Green Top Tube
(Lithium Heparin plasma separator tube with gel)
Alternate Specimen
Dried Blood collected on an AdvanceDx 100 card (Men Only)
Transport Temperature
Refrigerated (ship on frozen cold packs)
Stability
Refrigerated: 7 days
Lab Values
Total Testosterone
Males
| Sex/Age | Optimal (ng/dL) |
| Adult Male < 50 | 197.44 – 669.58 |
| Adult Male ≥50 | 187.72 – 684.19 |
| Pediatric Male 2-10 | <7.00 – 10.50 |
| Pediatric Male 11 | <7.00 – 478.50 |
| Pediatric Male 12 | <7.00 – 487.97 |
| Pediatric Male 13 | 8.28 – 549.79 |
| Pediatric Male 14 | 8.91 – 535.34 |
| Pediatric Male 15 | 65.96 – 756.50 |
| Pediatric Male 16-21 | 228.16 – 710.74 |
| Male Tanner Stage 1 | <7.00 -13.06 |
| Male Tanner Stage 2 | <7.00 – 79.13 |
| Male Tanner Stage 3 | <7.00 – 499.18 |
| Male Tanner Stage 4 | 79.10 – 747.17 |
| Male Tanner Stage 5 | 224.83 – 669.65 |
Alert values: N/A
Females
| Sex/Age | Optimal (ng/dL) |
| Adult Female <50 | 8.38 – 35.01 |
| Adult Female ≥50 | <7.00 – 35.92 |
| Pediatric Female 2-10 | <7.00 – 11.86 |
| Pediatric Female 11-15 | <7.00 – 27.57 |
| Pediatric Female 16-21 | 11.78 – 43.34 |
| Female Tanner Stage 1 | <7.00 – 10.06 |
| Female Tanner Stage 2 | <7.00 – 30.11 |
| Female Tanner Stage 3 | <7.00 – 30.49 |
| Female Tanner Stage 4 | <7.00 – 35.19 |
| Female Tanner Stage 5 | 11.80 – 39.30 |
Alert values: N/A
Clinical Significance
Total Testosterone
- Testosterone is used in the diagnosis and treatment of the following disorders:1-4
- Primary and secondary hypogonadism
- Delayed or precocious puberty
- Impotence in males
- Hirsutism (excessive hair) and virilization (masculinization) in females due to polycystic ovaries, tumors and adrenogenital syndromes
References:
- Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: Endocrine Society clinical practice guidelines. J Clin Endorcinol Metab. 2010;95(6):2536-2559.
- Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1-s66.
- Kopper NW, Gudeman J, Thompson DJ. Transdermal hormone therapy in postmenopausal women: a review of the metabolic eff ects and drug delivery technologies. Drug Des Devel Ther. 2008;2:193-202.
- Goodman N, Cobin RH. Reproductive disorders. In: Camacho PM, Gharib H, Sizemore GW, eds. Evidence-Based Endocrinology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2012:190-228.
Treatment Options
Total Testosterone
- Identify etiology of elevated or decreased total testosterone levels with physical assessment and additional diagnostic tests as indicated
- Treatment is based on etiology of abnormal hormone level
